[1] |
Hu YY, Liu CC, Shen ZQ, et al. Prevalence,risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang,China,2008-2018[J]. Emerg Microbes Infect, 2020, 9(1):1771-1779.
doi: 10.1080/22221751.2020.1799721
URL
|
[2] |
Zhang SG, Yang ZY, Sun LM, et al. Clinical Observation and Prognostic Analysis of Patients With Klebsiella pneumoniae Bloodstream Infection[J]. Front Cell Infect Microbiol, 2020, 10:577244.
|
[3] |
胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21(4):377-387.
doi: 10.16718/j.1009-7708.2021.04.001
|
[4] |
Zhang HJ, Guo Z, Chai Y, et al. Risk Factors for and Clinical Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Nosocomial Infections:A Retrospective Study in a Tertiary Hospital in Beijing,China[J]. Infect Drug Resist, 2021, 14:1393-1401.
doi: 10.2147/IDR.S298530
URL
|
[5] |
中华人民共和国卫生部办公厅. 医院感染诊断标准(试行)[EB/OL]. (2001-2-07) [2022-2-02]. http://www.nhc.gov.cn/wjw/gfxwj/201304/37cad8d95582456d8907ad04a5f3bd4c.shtml.
|
[6] |
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing,28th Edition: M100[S]. St. Louis, Missouri:CLSI, 2018.
|
[7] |
员静, 单斌, 孟雪斐, 等. 2018—2020年多中心耐碳青霉烯类肠杆菌目细菌的流行病学特征及耐药性分析[J]. 中国抗生素杂志, 2021, 46(11):1038-1043.
|
[8] |
van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2):a prospective cohort study[J]. Lancet Infect Dis, 2020, 20(6):731-741.
doi: 10.1016/S1473-3099(19)30755-8
URL
|
[9] |
Xu TT, Guo YQ, Ji Y, et al. Epidemiology and Mechanisms of Ceftazidime-Avibactam Resistance in Gram-Negative Bacteria[J]. Engineering, 2022, 11:138-145.
doi: 10.1016/j.eng.2020.11.004
URL
|
[10] |
Zhu WM, Yuan Z, Zhou HY. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients:a systematic review and meta-analysis[J]. Antimicrob Resist Infect Control, 2020, 9(1):23.
doi: 10.1186/s13756-020-0686-0
|
[11] |
Salomão MC, Freire MP, Boszczowski I, et al. Increased Risk for Carbapenem-Resistant Enterobacteriaceae Colonization in Intensive Care Units after Hospitalization in Emergency Department[J]. Emerg Infect Dis, 2020, 26(6):1156-1163.
doi: 10.3201/eid2606.190965
URL
|
[12] |
Magiorakos AP, Burns K, Rodríguez Baño J, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings:guidance from the European Centre for Disease Prevention and Control[J]. Antimicrob Resist Infect Control, 2017, 6:113.
doi: 10.1186/s13756-017-0259-z
URL
|
[13] |
刘琳, 刘志红. 糖皮质激素作用机制的研究进展[J]. 肾脏病与透析肾移植杂志, 2014, 23(5):472-476.
|
[14] |
Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers:a prospective observational multicentre study[J]. Clin Microbiol Infect, 2014, 20(12):1357-1362.
doi: 10.1111/1469-0691.12747
URL
|
[15] |
Vlad ND, Cernat RC, Carp S, et al. Predictors of carbapenem-resistant Enterobacteriaceae (CRE) strains in patients with COVID-19 in the ICU ward:a retrospective case-control study[J]. J Int Med Res, 2022, 50(10):3000605221129154.
|
[16] |
Madueño A, González García J, Ramos MJ, et al. Risk factors associated with carbapenemase-producing Klebsiella pneumoniae fecal carriage: A case-control study in a Spanish tertiary care hospital[J]. Am J Infect Control, 2017, 45(1):77-79.
doi: S0196-6553(16)30681-2
pmid: 27597392
|